Request Brochure

Covid 19 – We are fully operational during this time, taking calls 8am-8pm 7 days a week.

Ottawa researchers use stem cells to treat septic shock


In helping an eastern Ontario man recover from a near-fatal infection, researchers at The Ottawa Hospital say they have conducted the world’s first clinical trial using stem cells to treat septic shock.

Charles Berniqué from Hawkesbury developed an infection last June after his esophagus burst, possibly due to a severe case of food poisoning, according to a news release from the hospital.

The 73-year-old grandfather then went into septic shock, a potentially deadly condition that occurs when an uncontrolled infection leads to hyper-activation of the immune system, which can cause organs to fail.

Surgeons at The Ottawa Hospital placed him in an induced coma in intensive care, and consulted with his wife Maureen about taking part in a clinical trial using stem cells to treat septic shock.

She agreed, and within a day, Berniqué received an intravenous dose of mesenchymal stem cells grown in a hospital facility and originally extracted from the bone marrow of an Ottawa volunteer. He eventually recovered, and returned home after three months’ recovery.

The Ottawa Hospital’s trial is called “Cellular Immunotherapy for Septic Shock,” and is the result of research led by Dr. Duncan Stewart and Dr. Lauralyn McIntyre.

While mesenchymal stem cells have been used in clinical trials for other conditions, this is the first trial in the world to see how the cells specifically treat septic shock, according to the hospital’s news release.

More than 100,000 Canadians suffer from septic shock every year, and between 20 and 40 per cent of patients do not survive.Researchers say that while it’s too early to know the role the stem cells played in Berniqué’s recovery, they were encouraged by how his body tolerated them, and they plan to continue the therapy in more patients

Read the full article here

stem cell preservation

BSc (Hons) Microbiology

Chief Executive Officer | Biovault Family

Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.


Share This Article:


Categories:


Tags:

Request a Brochure

Find out more.

Our hope is that the information in this brochure will empower you as you weigh-up your cord blood and tissue storage options and prepare for your family’s healthy future.

Download your free guide to Biovault Family's cord blood banking!